Wegovy 2.4 mg Prefilled Pen

Wegovy 2.4 mg Prefilled Pen

Wegovy 2.4 mg FlexTouch is a prefilled pen containing semaglutide, a GLP-1 receptor agonist used as part of a comprehensive treatment programme for eligible patients. It is used alongside a reduced-calorie diet and increased physical activity.

Wegovy 2.4 mg is the standard once-weekly maintenance strength for many adults following the recommended dose-escalation schedule. Wegovy is a UK prescription-only medicine and should only be used according to the instructions of a qualified healthcare professional.

How Wegovy 2.4 mg Works

Semaglutide acts on GLP-1 receptors involved in appetite regulation. It can increase feelings of fullness and reduce hunger and food cravings, helping support reduced food intake alongside dietary and lifestyle measures.

Wegovy 2.4 mg Dose Information

The standard adult dose-escalation schedule gradually increases the weekly dose:

Period	Weekly dose
Weeks 1–4	0.25 mg
Weeks 5–8	0.5 mg
Weeks 9–12	1 mg
Weeks 13–16	1.7 mg
From week 17	2.4 mg maintenance dose

The dose should be increased only according to the treatment plan provided by your healthcare professional. If significant gastrointestinal symptoms occur, dose escalation may need to be delayed or adjusted by the prescriber.

Who May Be Prescribed Wegovy?

UK prescribing information includes Wegovy for weight management in eligible adults with obesity, or overweight with at least one weight-related health condition, alongside a reduced-calorie diet and increased physical activity. Eligibility should be assessed by an appropriate healthcare professional.

Important Safety Information

• Wegovy is a prescription-only medicine in the UK.
• Use Wegovy exactly as prescribed by your healthcare professional.
• Do not use Wegovy together with another semaglutide-containing medicine or another GLP-1 receptor agonist unless specifically instructed.
• Common side effects may include nausea, vomiting, diarrhoea, constipation, abdominal pain, headache and tiredness.
• Seek urgent medical attention if you experience severe and persistent abdominal pain.
• Tell your healthcare professional about all medicines you are taking, particularly insulin or sulfonylureas.
• Wegovy should not be used during pregnancy. Discuss pregnancy plans with your healthcare professional.

Wegovy 2.4 mg Prefilled Pen Information

• Active ingredient: Semaglutide
• Strength: 2.4 mg per dose
• Administration: Subcutaneous injection
• Frequency: Once weekly, as prescribed
• Pen type: FlexTouch prefilled pen
• Contents: Four 2.4 mg doses
• Total semaglutide: 9.6 mg in 3 mL
• Prescription status: Prescription-only medicine (POM)

Related Wegovy Products

If you are following the Wegovy dose-escalation programme, you can also review the Wegovy 1.7 mg Prefilled Pen and Wegovy 7.2 mg Prefilled Pen, where appropriate. You can also explore the complete Wegovy Products range.

For general information, visit our Weight Management Guide.

Official UK Medicine Information

For the latest official prescribing and patient information, see the Wegovy 2.4 mg Patient Information Leaflet on the electronic Medicines Compendium (eMC).

Frequently Asked Questions

What is Wegovy 2.4 mg?

Wegovy 2.4 mg is a semaglutide prefilled injection pen used as the standard maintenance strength for many adults following the recommended dose-escalation schedule.

Is Wegovy 2.4 mg prescription only?

Yes. Wegovy is classified as a prescription-only medicine in the UK.

How often is Wegovy 2.4 mg used?

Wegovy is administered once weekly according to the treatment plan prescribed by a healthcare professional.

Is 2.4 mg the maintenance dose?

Yes. For the standard adult weight-management schedule, 2.4 mg once weekly is the maintenance dose.

Can I start directly with Wegovy 2.4 mg?

No. The standard treatment schedule begins at a lower dose and increases gradually to reduce the likelihood of gastrointestinal side effects. Follow the dosing instructions provided by your prescriber.

Can Wegovy 2.4 mg be used with another GLP-1 medicine?

Wegovy should not be combined with another GLP-1 receptor agonist or another semaglutide-containing medicine unless specifically directed by a healthcare professional.

Where can I find official information about Wegovy 2.4 mg?

The UK electronic Medicines Compendium provides the official Patient Information Leaflet and Summary of Product Characteristics for Wegovy.